Risk of hereditary cancers is assessed by taking into account familial and personal factors or clinicopathological characteristics of cancers such as triple-negative breast cancers (TNBC), which do not express the genes for estrogen receptor (ER), progesterone receptor (PR), or HER2 receptor [4]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.